Novartis | search
Click here to view Novartis news from 60+ newspapers.
Bookmark or Share- Boehringer Ingelheim | Cafepharma Message Boards | Pharma Sales, Device ...Thurs news: Novartis buys Kate Therapeutics. Trump’s likely FDA pick. Bayer tries for new Nubeqa indications. New CSO for Amgen. Versant developing new type of obesity drug. See more on our front page
- Pfizer | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab SalesAnonymous board for Pfizer. General Discussion CP Bulletin Important: Board Posting Policies Ask the Webmaster CP Group Discussion The Darkened Sample Closet Latest CP Job Ratings Ask a Whistleblower Attorney Employment Harassment & Discrimination Forum Healthcare Reform Discussions Cafepharma Playground In the Pipe MyPharma Sports Talk Fitness and Nutrition Political Discussions The Politics ...
- Amgen | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab SalesAnonymous board for Amgen. General Discussion CP Bulletin Important: Board Posting Policies Ask the Webmaster CP Group Discussion The Darkened Sample Closet Latest CP Job Ratings Ask a Whistleblower Attorney Employment Harassment & Discrimination Forum Healthcare Reform Discussions Cafepharma Playground In the Pipe MyPharma Sports Talk Fitness and Nutrition Political Discussions The Politics ...
- Cafepharma | Pharmaceutical Sales, Medical Sales, Lab SalesNovartis will then potentially move candidates forward through the clinic, according to a Nov. 20 release. Novartis taps Vyriad’s viral vectors to develop in vivo T cell editing Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from Chinese news outlets and confirmation from ...
- Cafepharma | Pharmaceutical Sales, Medical Sales, Lab SalesCafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.
More
